|
Report Date : |
13.11.2013 |
IDENTIFICATION DETAILS
|
Name : |
GEMINI INDÚSTRIA DE INSUMOS FARMACÊUTICOS LTDA |
|
|
|
|
Registered Office : |
VIA Primária 4D - S/Nº, Quadra,8 -A - Módulos I |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
23.01.2009 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacture, import and distribution of pharmaceutical products. |
|
|
|
|
No. of Employees : |
116 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
|
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BRAZIL - ECONOMIC OVERVIEW
Characterized by large and well-developed agricultural,
mining, manufacturing, and service sectors, Brazil's economy outweighs that of
all other South American countries, and Brazil is expanding its presence in
world markets. Since 2003, Brazil has steadily improved its macroeconomic
stability, building up foreign reserves, and reducing its debt profile by
shifting its debt burden toward real denominated and domestically held
instruments. In 2008, Brazil became a net external creditor and two ratings
agencies awarded investment grade status to its debt. After strong growth in
2007 and 2008, the onset of the global financial crisis hit Brazil in 2008.
Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based
exports dwindled and external credit dried up. However, Brazil was one of the
first emerging markets to begin a recovery. In 2010, consumer and investor
confidence revived and GDP growth reached 7.5%, the highest growth rate in the
past 25 years. Rising inflation led the authorities to take measures to cool
the economy; these actions and the deteriorating international economic
situation slowed growth to 2.7% in 2011, and 1.3% in 2012. Unemployment is at
historic lows and Brazil's traditionally high level of income inequality has
declined for each of the last 14 years. Brazil's historically high interest
rates have made it an attractive destination for foreign investors. Large
capital inflows over the past several years have contributed to the
appreciation of the currency, hurting the competitiveness of Brazilian
manufacturing and leading the government to intervene in foreign exchange
markets and raise taxes on some foreign capital inflows. President Dilma
ROUSSEFF has retained the previous administration's commitment to inflation
targeting by the central bank, a floating exchange rate, and fiscal restraint.
In an effort to boost growth, in 2012 the administration implemented a somewhat
more expansionary monetary policy that has failed to stimulate much growth
Source
: CIA
GEMINI INDÚSTRIA DE
INSUMOS FARMACÊUTICOS LTDA
|
MAIN ADDRESS: |
VIA PRIMÁRIA 4D - S/Nº, QUADRA,8 -A - MÓDULOS I E II - DAIA |
|
ZIP CODE/CITY: |
75133-590 - ANÁPOLIS/GO |
|
|
|
|
PHONE: |
62 4014-9100 |
|
FAX: |
62 4014-9102 |
|
E-MAIL: |
financeiro@purifarma.com.br |
|
BRANCHES: |
|
NOT AVAILABLE. |
|
MAIN ACTIVITIES: |
|
MANUFACTURE, IMPORT AND DISTRIBUTION OF PHARMACEUTICAL PRODUCTS. |
|
LEGAL FORM: |
LIMITED LIABILITY COMPANY |
|
|
|
|
INCORPORATION DATE: |
23/01/2009 |
|
REGISTER DATE: |
12/03/2009 |
|
BALANCE SHEET FILING DATE: |
31/12 |
|
TAX CONTRIBUTOR NUMBER(CNPJ): |
10.690.195/0001-00 |
|
STATE REGISTER: |
10.450.596-6 |
|
|
|
|
SHARE CAPITAL: |
R$ 10.000.000,00 |
|
|
|
|
JÚLIO TOMIZO TANAKA |
MANAGING PARTNER |
|
VALDETE VIODRES TANAKA |
MANAGING PARTNER |
|
THE MANAGING PARTNERS ARE AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY. |
|
SHAREHOLDERS / PARTNERS: |
|
|
|
|
|
JÚLIO TOMIZO TANAKA |
50% |
|
VALDETE VIODRES TANAKA |
50% |
|
AFFILIATES / SUBSIDIARIES: |
|
|
A SCAN THROUGH
OUTSIDE SOURCES SHOWED THE SUBJECT AND/OR DIRECTORS HAS/HAVE THE FOLLOWING
UNCONFIRMED HOLDINGS: |
|
|
LEVIALE - INDÚSTRIA COSMÉTICA LTDA |
|
|
GENIX - INDÚSTRIA FARMACÊUTICA LTDA |
|
|
PURIFARMA DISTRIBUIDORA QUÍMICA E FARMACÊUTICA LTDA |
|
|
BISNAGO INDÚSTRIA DE EMBALAGENS LTDA |
|
|
J. V. T. - CONSTRUTORA E INCORPORADORA LTDA. |
|
|
LVA PARTICIPAÇÕES LTDA. |
|
|
FARMACEUTICAL COML. IMPORTAÇÃO E EXPORTAÇÃO LTDA |
|
|
LEVIALE COMERCIAL DE COSMÉTICOS LTDA |
|
|
THE SUBJECT WAS ESTABLISHED ON JANUARY 23, 2009 TO BE ENGAGED IN THE SAID LINE OF BUSINESS AND UP TO DATE IT IS STILL OPERATING WITHIN THE GENERAL SCENE REPORTED HEREIN. TRADE NAME "GEMINI INDÚSTRIA E COMÉRCIO LTDA". THE CONTACTS WERE MADE THROUGH THE PHONE 11 2067-5610 / FAX 11 2215-8823 AT THE COMPANY OF THE GROUP "PURIFARMA DISTRIBUIDORA QUÍMICA E FARMACÊUTICA LTDA". THE E-MAIL "FINANCEIRO@PURIFARMA.COM.BR" ALSO BELONGS TO THE REFERRED COMPANY. FURTHER DETAILS ARE SO FAR NOT KNOWN. WHEN INTERVIEWED SOURCES AT THE SUBJECT STATED THAT ARE STILL WAITING FOR AUTHORIZATION FROM THE PRINCIPALS TO PROVIDE THE DATA NECESSARY TO COMPLETE THIS REPORT. A REQUEST FOR FURTHER DATA HAS BEEN SENT TO THE COMPANY. PROVIDED THE DATA REQUESTED ARE RECEIVED FROM THE SUBJECT A COMPLEMENTARY REPORT WILL BE SENT TO YOUR ATTENTION. THE DATA CONTAINED HEREIN WERE OBTAINED FROM OUTSIDE SOURCES, OUR DATABASE AND OFFICIAL. NO FURTHER DATA WAS AVAILABLE WITH SEVERAL SOURCES USUALLY INVESTIGATED. |
|
PUBLIC INFORMATION: |
|
NO DETRIMENTAL FILES WERE FOUND. |
|
GENERAL BALANCE SHEETS AS OF 31/12/2011, 31/12/2010 AND 31/12/2009. |
|
( FIGURES ARE IN REAIS ). |
|
ASSETS |
|
|
|
|
CURRENT: |
31/12/2011 |
31/12/2010 |
31/12/2009 |
|
|
|
|
|
|
CASH |
4.571,92 |
95,71 |
673,67 |
|
BANKS |
95.979,38 |
70.721,09 |
5.586,65 |
|
ADVANCES |
231.647,95 |
33.232,81 |
7.474,17 |
|
CLIENTS |
2.253.800,47 |
541.528,98 |
|
|
RECOVERABLE TAXES |
145.955,04 |
14.869,24 |
|
|
INVENTORY |
4.801.016,91 |
1.434.306,25 |
|
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL CURRENT ASSETS |
7.532.971,67 |
2.094.754,08 |
13.734,49 |
|
FIXED ASSETS: |
|
|
|
|
|
|
|
|
|
FIXED ASSETS |
1.366.107,56 |
911.083,18 |
840.005,25 |
|
DEFERRED |
196.044,03 |
218.664,49 |
33.348,80 |
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL FIXED ASSETS |
1.562.151,59 |
1.129.747,67 |
873.354,05 |
|
|
================ |
================ |
================ |
|
TOTAL ASSETS |
9.095.123,26 |
3.224.501,75 |
887.088,54 |
|
LIABILITIES: |
|
|
|
|
CURRENT: |
31/12/2011 |
31/12/2010 |
31/12/2009 |
|
|
|
|
|
|
SALARIES PAYABLE |
9.869,97 |
7.307,92 |
4.088,87 |
|
SOCIAL OBLIGATIONS |
6.961,17 |
5.214,50 |
3.667,33 |
|
PROVISIONS |
12.708,62 |
9.985,93 |
1.773,17 |
|
TAXES & CONTRIBUTIONS |
372.820,34 |
117.748,27 |
1.813,87 |
|
ACCOUNTS PAYABLE |
155.262,65 |
1.385,85 |
34.745,30 |
|
SUPPLIERS |
2.335.307,04 |
644.223,16 |
|
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL CURRENT LIABILITIES |
2.892.929,79 |
785.865,63 |
46.088,54 |
|
LONG TERM
LIABILITIES: |
|
|
|
|
|
|
|
|
|
LOANS AND FINANCING |
3.286.533,96 |
1.434.487,07 |
|
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL LONG TERM LIABILITIES |
3.286.533,96 |
1.434.487,07 |
|
|
NET EQUITY: |
|
|
|
|
|
|
|
|
|
SHARE CAPITAL |
3.000.000,00 |
3.000.000,00 |
3.000.000,00 |
|
UNPAID CAPITAL |
-1.810.000,00 |
-1.929.000,00 |
-2.159.000,00 |
|
ACCRUED PROFIT (LOSS) |
1.725.659,51 |
-66.850,94 |
|
|
|
---------------- |
---------------- |
---------------- |
|
TOTAL NET EQUITY |
2.915.659,51 |
1.004.149,06 |
841.000,00 |
|
|
================ |
================ |
================ |
|
TOTAL LIABILITIES |
9.095.123,26 |
3.224.501,76 |
887.088,54 |
|
PROFIT AND LOSS ACCOUNTS AS OF 31/12/2011, 31/12/2010 AND 31/12/2009. |
|
( FIGURES ARE IN REAIS ). |
|
|
31/12/2011 |
31/12/2010 |
31/12/2009 |
|
|
|
|
|
|
GROSS SALES |
17.047.269,22 |
1.742.609,70 |
|
|
(-) TAXES ON SALES |
2.301.844,48 |
243.364,18 |
|
|
|
---------------- |
---------------- |
---------------- |
|
NET SALES |
14.745.424,74 |
1.499.245,52 |
|
|
(-) COST OF SOLD GOODS |
11.829.208,29 |
1.380.437,80 |
|
|
|
---------------- |
---------------- |
---------------- |
|
GROSS PROFIT |
2.916.216,45 |
118.807,72 |
|
|
OPERATING REVENUE (EXPENSE) |
-294.429,70 |
-145.364,33 |
|
|
FINANCIAL REVENUE(EXPENSE) |
-287.916,67 |
16.413,98 |
|
|
|
---------------- |
---------------- |
---------------- |
|
OPERATIONAL PROFIT (LOSS) |
2.333.870,08 |
-10.142,63 |
|
|
CONTRIBUTION/INCOME TAX |
-541.359,63 |
-56.708,31 |
|
|
|
---------------- |
---------------- |
---------------- |
|
NET PROFIT (LOSS) |
1.792.510,45 |
-66.850,94 |
|
|
MONTHLY SALES |
|||
|
|
2012 |
|
|
|
|
--------------------- |
|
|
|
JANUARY |
R$ 2.113.452,64 |
|
|
|
FEBRUARY |
R$ 1.332.230,83 |
|
|
|
MARCH |
R$ 2.175.512,75 |
|
|
|
APRIL |
R$ 1.792.306,22 |
|
|
|
MAY |
R$ 3.789.613,79 |
|
|
|
JUNE |
R$ 4.847.726,72 |
|
|
|
JULY |
|
|
|
|
AUGUST |
|
|
|
|
SEPTEMBER |
|
|
|
|
OCTOBER |
|
|
|
|
NOVEMBER |
|
|
|
|
DECEMBER |
|
|
|
|
TOTAL |
R$ 16.050.842,95 |
|
|
|
RATIOS: |
31/12/2011 |
31/12/2010 |
31/12/2009 |
|
QUICK RATIO |
,94 |
|
,84 |
|
,30 |
|
|
CURRENT RATIO |
2,60 |
|
2,67 |
|
,30 |
|
|
ACCOUNTS RECEIVABLE TURNOVER |
6,54 |
TIMES |
2,77 |
TIMES |
|
|
|
DAYS' SALES IN RECEIVABLES |
55,03 |
DAYS |
130,03 |
DAYS |
|
|
|
INVENTORY TURNOVER |
2,46 |
TIMES |
,96 |
TIMES |
|
|
|
ACCOUNTS PAYABLE PERIOD |
71,07 |
DAYS |
168,00 |
DAYS |
|
|
|
RETURN ON ASSETS |
1,62 |
TIMES |
,47 |
TIMES |
|
|
|
SALES TURNOVER ON NET EQUITY |
5,06 |
TIMES |
1,49 |
TIMES |
|
|
|
NET WORTH TIE-UP |
,47 |
|
,91 |
|
1,00 |
|
|
INDEBTEDNESS |
2,12 |
|
2,21 |
|
,05 |
|
|
EQUITY RATIO |
32,06 |
% |
31,14 |
% |
94,80 |
% |
|
WORKING CAPITAL RATIO |
160,39 |
% |
166,55 |
% |
-70,20 |
% |
|
GENERAL SOLVENCY |
1,47 |
|
1,45 |
|
19,25 |
|
|
RETURN ON NET EQUITY |
61,48 |
% |
-6,66 |
% |
|
|
|
RETURN ON SALES (PROFIT MARGIN) |
12,16 |
% |
-4,46 |
% |
|
|
|
GROSS PROFIT MARGIN |
19,78 |
% |
7,92 |
% |
|
|
|
OPERATIONAL RESULT |
15,83 |
% |
-,68 |
% |
|
|
|
SALES TURNOVER ON LIABILITIES |
5,10 |
TIMES |
1,91 |
TIMES |
|
|
|
FOREIGN CURRENCY ON ASSETS |
|
|
|
|
|
|
|
FOREIGN CURRENCY ON LIABILITIES |
|
|
|
|
|
|
|
FOLLOWS ATTACHED WORKSHEET WITH MAIN FINANCIAL RATIOS. THE FIGURES AVAILABLE SHOW A SATISFACTORY FINANCIAL STANDING. THE LEVEL OF INDEBTEDNESS IS VERY HIGH BUT IT IS NOTED GOOD CURRENT RATIO AND POSITIVE WORKING CAPITAL AMOUNT. IN ADDITION IT SHOWS HIGH GROWING SALES AND PROFITABILITY. REMARKS: THE 2009 PROFIT AND LOSS ACCOUNT IS NOT AVAILABLE DUE TO THE FACT THAT THE COMPANY STARTED ITS OPERATIONS IN 2010 ONLY. |
OWNED PREMISES ARE VALUED AT R$ 890.781,51
NOT AVAILABLE
NOT AVAILABLE
|
NOT AVAILABLE. |
|
|
BRANCH/PHONE: |
|
|
BANCO DO BRASIL S/A |
3388-X / 62 3311-1633 |
|
|
REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO PROVIDE ANY BANKING DETAILS. ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY HAS NO RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK"). DATE RESEARCHED NOVEMBER 07, 2013. |
|
MANUFACTURE, IMPORT AND DISTRIBUTION OF PHARMACEUTICAL PRODUCTS. |
|
IMPORT AND EXPORT: |
IMPORTS FROM:
|
NOT AVAILABLE. |
EXPORTS TO:
|
NOT AVAILABLE. |
|
MAIN CLIENTS: |
|
|
|
|
|
|
|
DOMESTIC CLIENTS: |
|
|
|
NOT AVAILABLE. |
|
|
|
STAFF: |
|
|
|
THE COMPANY HAS: 116 EMPLOYEE(S) |
|
THE SUBJECT IS A NEWLY-ESTABLISHED COMPANY, OPERATING SINCE 2009. SO FAR IT HAS A CLEAR TRADE HISTORY AND MODEST PAYMENT BEHAVIOR. THE COMPANY HAS TRADE RELATIONS WITH SOME LOCAL SUPPLIERS BUT UP TO DATE ONLY SMALL PAYMENTS WERE REPORTED AND THE SUBJECT IS NOT SAID TO BE USER OF TRADE CREDIT FACILITIES. |
|
MAIN SUPPLIERS: |
|
|
|
|
|
|
|
DOMESTIC SUPPLIERS: |
|
|
|
NOT AVAILABLE. |
|
|
|
PAYMENT HISTORY: |
|
2 SUPPLIERS REPORTED PAYMENTS: |
|
TOTAL AMOUNT: R$ 2.989,00 |
|
|
|
AMOUNT OF INVOICES PAID: 6 |
|
TOTAL OF PROMPT PAYMENTS: 100% |
|
HIGHEST INVOICE: R$ 726,00 |
|
HIGHEST CREDIT: R$ 967,00 |
|
BASED ON THE OVERALL DATA AVAILABLE THE SUBJECT MAY BE CONSIDERED FOR NORMAL BUSINESS COMMITMENTS. CREDIT FACILITIES HOWEVER SHOULD BE GRANTED ON MODERATE AMOUNTS ONLY DUE TO THE FACT THAT THE COMPANY STARTED ITS OPERATIONS RECENTLY. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.59 |
|
|
1 |
Rs.101.56 |
|
Euro |
1 |
Rs.85.15 |
INFORMATION DETAILS
|
Report
Prepared by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome
financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.